National Cancer Institute/National Toxicology Program (NCI/NTP) Technical Reports that Are Not Included in Carcinogenic Potency Database (CPDB)

1. Test Agent Exclusions

A. Particulate

| | | | | | | | Exclusion |
|-----|--|------|-----------|------|--------|-------|-----------|
| TR# | Chemical name | Year | MR | FR | MM | FM | Rule |
| 279 | Asbestos, amosite | 1991 | N | N | | | pt |
| 249 | Asbestos, amosite | 1987 | | Hams | ster=N | | pt |
| 279 | Asbestos, amosite + dimethyl hydrazine | 1991 | IS | IS | | | co,pt |
| 295 | Asbestos, chrysotile(IR) | 1986 | SE | NE | | | pt |
| 246 | Asbestos, chrysotile(IR) | 1991 | | Hams | ster=N | | pt |
| 295 | Asbestos, chrysotile(IR) | 1986 | | | | | pt |
| 246 | Asbestos, chrysotile(IR) + Dimethyl | 1991 | Hamster=I | | | co,pt | |
| | hydrazine | | | | | | |
| 295 | Asbestos, chrysotile(IR) + Dimethyl | 1986 | IS | IS | | | co,pt |
| | hydrazine | | | | | | |
| 295 | Asbestos, chrysotile(SR) | 1986 | NE | NE | | | pt |
| 246 | Asbestos, chrysotile(SR) | 1991 | Hamster=N | | | | pt |
| 280 | Asbestos, crocidolite | 1989 | N | N | | | pt |
| 277 | Asbestos, tremolite | 1990 | | | | | pt |
| 492 | Gallium arsenide | 2000 | NE | CE | NE | NE | pt |
| 499 | Indium phosphide | 2001 | CE | CE | CE | CE | pt |
| 451 | Nickel oxide | 1996 | SE | SE | NE | EE | pt |
| 453 | Nickel subsulfide | 1996 | CE | CE | NE | NE | pt |
| 421 | Talc | 1993 | SE | CE | NE | NE | pt |

B. Magnetic Field

| | | | | | | | Exclusion |
|-----|----------------------------------|------|----|----|----|----|-----------|
| TR# | Chemical name | Year | MR | FR | MM | FM | Rule |
| 488 | 60-Hz Magnetic Fields | 1999 | EE | NE | NE | NE | mf |
| 489 | Magnetic Field + DMBA Initiation | 1999 | | | | | co,mf |
| | Promotion | | | | | | |

C. Cocarcinogenesis

| | | | | | | | Exclusion |
|-----|------------------|------|----|----|----|----|-----------|
| TR# | Chemical name | Year | MR | FR | MM | FM | Rule |
| 440 | Ozone/NNK | 1995 | | | | | со |
| 510 | Urethane/ethanol | 2004 | | | IS | IS | co |

2. Route exclusions

A. Dermal

| | | | | | | | Exclusion |
|-----|---|------|----|----|----|----|-----------|
| TR# | Chemical name | Year | MR | FR | MM | FM | Rule |
| 444 | o-Benzyl-p-chlorophenol | 1995 | | | | | sp |
| 438 | Benzethonium chloride | 1995 | NE | NE | NE | NE | sp |
| 441 | Comparative mouse skin paint studies | 1996 | | | | | sp |
| 400 | 2,3-Dibromo-1-propanol | 1993 | CE | CE | CE | CE | sp |
| 310 | Diesel fuel marine | 1986 | | | EE | EE | sp |
| 478 | Diethanolamine | 1999 | NE | NE | CE | CE | sp |
| 429 | Diethyl phthalate | 1995 | NE | NE | EE | EE | sp |
| 429 | Diethyl phthalate/dimethyl phthalate | 1995 | | | | | co,sp |
| 456 | 1,2-Dihydro-2,2,4-trimethylquinoline | 1997 | SE | NE | NE | NE | sp |
| 202 | 1,2,3,6,7,8-Hexachlorodibenzo- <i>p</i> -dioxin | 1981 | | | N | N | sp |
| 480 | Lauric acid diethanolamine condensate | 1999 | NE | NE | NE | SE | sp |
| 310 | Navy fuels JP-5 | 1986 | | | NE | NE | sp |
| 417 | <i>p</i> -Nitrophenol | 1993 | | | NE | NE | sp |
| 481 | Oleic acid diethanolamine condensate | 1999 | NE | NE | NE | NE | sp |
| 301 | o-Phenylphenol | 1986 | | | NE | NE | sp |
| 197 | Selenium Sulfide | 1982 | | | N | N | sp |
| 199 | Selsun | 1982 | | | N | N | sp |
| 464 | Sodium xylenesulfonate | 1995 | NE | NE | NE | NE | sp |
| 201 | 2,3,7,8-Tetrachlorodibenzo- <i>p</i> -dioxin | 1982 | | | Е | P | sp |
| 449 | Triethanolamine | 1999 | EE | NE | IS | IS | sp |
| 518 | Triethanolamine | 2004 | | | EE | SE | sp |
| 362 | 4-Vinyl-1-cyclohexene diepoxide | 1990 | CE | CE | CE | CE | sp |

B. Subcutaneous

| TR# | Chemical name | Year | MR | FR | MM | FM | Exclusion Rule |
|-----|----------------------|------|----|----|----|----|-------------------|
| 469 | AZT/α-interferon A/D | 1999 | | | | | co,sc |
| 469 | Interferon A/D | 1999 | | | | | sc |
| 469 | Interferon A | 1999 | | | | | sc |

C. Intravaginal Studies

| | | | | | | | Exclusion |
|-----|-------------------|------|----|----|----|----|-----------|
| TR# | Chemical name | Year | MR | FR | MM | FM | Rule |
| 474 | Polyvinyl Alcohol | 1996 | | | | NE | vg |

3. *In utero* exposure

| | | | | | | | Exclusion |
|-----|------------------------------------|------|----|----|----|----|-----------|
| TR# | Chemical name | Year | MR | FR | MM | FM | Rule |
| 463 | D&C Yellow no. 11 | 1997 | SE | SE | | | ut |
| 278 | 2,6-Xylidine (2,6-dimethylaniline) | 1990 | P | P | | | ut |

4. Feed restriction studies

| | | | | | | | Exclusion |
|-----|--------------------------|------|----|----|----|----|-----------|
| TR# | Chemical name | Year | MR | FR | MM | FM | Rule |
| 460 | Feed restriction studies | 1997 | | | | | re |

Sex-Species Codes: MR=male rats, FR=female rats, MM=male mice, FM=female mice **Exclusion Rules:**

| Code | Definition |
|------|-------------------|
| со | cocarcinogenesis |
| re | feed restriction |
| mf | magnetic field |
| pt | particulate |
| sp | skin painting |
| sc | subcutaneous |
| ut | in utero exposure |
| vg | intravaginal |

NTP Status Report Evaluations:

| | tatus Report Evaluations. |
|---------|---|
| Code | Definition |
| CE | Clear Evidence of Carcinogenic Activity is demonstrated by studies that are interpreted as showing a dose-related (i) increase of malignant neoplasms, (ii) |
| | increase of a combination of malignant and benign neoplasms, or (iii) marked |
| | increase of benign neoplasms if there is an indication from this or other studies |
| ~- | of the ability of such tumors to progress to malignancy. |
| SE | Some Evidence of Carcinogenic Activity is demonstrated by studies that are interpreted as showing a chemical-related increased incidence of neoplasms |
| | (malignant, benign, or combined) in which the strength of the response is less than that required for clear evidence. |
| EE | Equivocal Evidence of Carcinogenic Activity is demonstrated by studies that are |
| | interpreted as showing a marginal increase of neoplasms that may be chemically related. |
| NE | No Evidence of Carcinogenic Activity is demonstrated by studies that are |
| | interpreted as showing no chemical-related increases in malignant or benign neoplasms. |
| IS | Inadequate Study of Carcinogenic Activity is demonstrated by studies that |
| | because of major qualitative or quantitative limitations cannot be interpreted as |
| | valid for showing either the presence or absence of carcinogenic activity. |
| Earlier | Designations |
| P | Positive |
| Е | Equivocal |
| N | Negative |